ArticlePostepy dermatologii i alergologii2026
The effect of omalizumab treatment on inflammatory parameters in urticarial diseases: a retrospective study.
Article in Postepy dermatologii i alergologii, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic spontaneous urticaria (CSU) and urticarial vasculitis (UV) are chronic inflammatory skin disorders. Monoclonal anti-IgE therapy is widely approved for CSU and is increasingly investigated for its broader immunomodulatory effects. Aim: This study aimed to evaluate the impact of anti-IgE therapy on systemic inflammatory markers, including complete blood count (CBC)-derived ratios and C-reactive protein (CRP), in patients with CSU and UV. Material and methods: In this retrospective study, 80 patients (67 with CSU, 13 with UV) who received anti-IgE therapy for at least 12 weeks were analysed. Pre- and post-treatment values of hematologic parameters (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], neutrophil-to-monocyte ratio [NMR], lymphocyte-to-monocyte ratio [LMR], mean platelet volume [MPV], red cell distribution width [RDW]) and CRP were compared. Correlation analyses were also performed. Results: In the CSU group, significant reductions were observed in neutrophil count, CRP, NLR, PLR, and NMR, whereas lymphocyte count increased ( Conclusions: Anti-IgE therapy demonstrated measurable anti-inflammatory effects in CSU, reflected by reductions in CRP and CBC-derived markers, which may serve as accessible biomarkers for monitoring treatment response. The effect was less evident in UV, possibly due to distinct disease mechanisms. Larger prospective studies in UV populations are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.